Deficient lung surfactant apoproteins in amniotic fluid with mature phospholipid profile from diabetic pregnancies

Katyal, Sikandar L.; Amenta, Joseph S.; Singh, Gurmukh; Silverman, Jeffrey A.

doi:10.1016/s0002-9378(84)80031-9

Cited by 61 publications

(29 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Monitoring surfactant and surfactant apoprotein in amniotic fluids has proven to be a reliable assay for assessing pulmonary maturity of the fetus (8,9). Markers for airway cells could be used in the same vein, however, teleologically surfactant and surfactant apoprotein assays would have an advantage as means of testing pulmonary maturity.…”

Section: Resultsmentioning

confidence: 99%

“…Examination of airway cells has been limited to morphologic studies (5,6). Studies of pulmonary surfactant have led to the development of clinical tests useful for assessing pulmonary maturity of the fetus in utero (7)(8)(9). In particular, an assay for surfactant apoprotein appears to be promising in accurate determination of the development of the surfactant system (9).…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Quantitative Assay for a Clara Cell-Specific Protein and Its Application in the Study of Development of Pulmonary Airways in the Rat

1986

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

A Quantitative Assay for a Clara Cell-Specific Protein and Its Application in the Study of Development of Pulmonary Airways in the Rat

1986

View full text Add to dashboard Cite

“…The most commonly used test involves the lecithin1 sphingomyelin ratio, but other markers are also available such as the concentration of lecithin or phosphatidylglycerol, the foam stability index, or the surfactant apoproteins, which appear to have a better predictability in diabetic pregnancy, a situation associated with a particularly elevated risk of neonatal RDS (18)(19)(20)(21). All these tests are based on surfactant constituents-which are deficient in neonatal RDS-and thus reflect the maturation of lung alveoli.…”

Section: Discussionmentioning

confidence: 99%

Clara Cell Protein in Human Amniotic Fluid: A Potential Marker of Fetal Lung Growth

et al. 1994

View full text Add to dashboard Cite

Clara cell protein (CC16) is a 16-kD protein secreted at the surface of respiratory airways by nonciliated bronchial and bronchiolar cells, including Clara cells. Using the same immunoassay as that recently developed for CC16 in lung lavage, we have measured CC16 in amniotic fluid samples from 100 normal fetuses and 51 fetuses with various pathologies. Ouchterlony immunodiffusion analysis showed a complete identity between CC16 in amniotic fluid and the protein in lung lavages of adults. CC16 was detectable in amniotic fluid from about the 15th wk of pregnancy, then progressively increased until delivery, with a tendency to reach a plateau after the 30th wk. Between the 15th and the 39th wk of pregnancy, the concentration of CC16 in amniotic fluid increased on average 25 times. The sex of the fetus did not influence the concentration of CC16 in amniotic fluid. Compared with expected values, levels of CC16 in amniotic fluid were on average not significantly altered in cases of spina bifida (n = 9), anencephaly (n = 7), and trisomy 21 (n = 6). In contrast, CC16 was on average significantly decreased in cases of diaphragmatic hernia (n = 6), trisomy 18 (n = 14), Turner syndrome (n = 4), and diabetic pregnancy (n = 5). In cases of diaphragmatic hernia, a relation emerged between the concentration of CC16 in amniotic fluid and both the weight of the lungs and the survivorship of the fetuses. The time course of CC16 in amniotic fluid during normal pregnancy and its reduction in pathologies associated with lung hypoplasia suggest that CC16 in amniotic fluid might serve as a marker of bronchial epithelium growth. (Pediatr Res 36: 771-775, 1994)

show abstract

“…Its concentration in amniotic fluid increases during the third trimester of gestation parallelling the increase in surfactant phospholipids during that period [7,13,23], Measurement of the SP-A concentration in amniotic fluid has therefore been used to assess lung maturity [11,12,14,22].…”

Section: Introductionmentioning

confidence: 99%

Surfactant protein A in the course of respiratory distress syndrome

et al. 1992

View full text Add to dashboard Cite

Abstract. Surfactant-associated protein (SP-A) was measured in tracheal aspirates of ventilated infants with (n = 51) and without (n = 21) respiratory distress syndrome (RDS). SP-A concentrations in samples collected after birth were significantly lower in RDS than in infants ventilated for other reasons than RDS (median 0.03 vs. 1.60 gg/ml). As a biochemical test to diagnose RDS early after birth, the sensitivity of measuring SP-A in tracheal aspirates was 87% and specificity 81%. SP-A content in tracheal aspirates of infants with RDS was monitored during the first 7 days of life. A significant (P < 0.001) increase within the first 4 days was found in those infants who survived, whereas no such change was found in those infants who died.

show abstract

Deficient lung surfactant apoproteins in amniotic fluid with mature phospholipid profile from diabetic pregnancies

Cited by 61 publications

References 12 publications

A Quantitative Assay for a Clara Cell-Specific Protein and Its Application in the Study of Development of Pulmonary Airways in the Rat

A Quantitative Assay for a Clara Cell-Specific Protein and Its Application in the Study of Development of Pulmonary Airways in the Rat

Clara Cell Protein in Human Amniotic Fluid: A Potential Marker of Fetal Lung Growth

Surfactant protein A in the course of respiratory distress syndrome

Contact Info

Product

Resources

About